Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07077083 | CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC(CAIX PET/CT) | not yet recruiting | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07714447 | Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 91 | Sun Yat-sen UniversityOTHER | 1 | Jul 21, 2026 |
| clinicaltrials |
| NCT07716046 | Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer(FACET) | not yet recruiting | Phase 2 | 240 | Fudan UniversityOTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT07713459 | A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | not yet recruiting | Phase 2 | 105 | Kure Cells, INCINDUSTRY | 0 | Jul 20, 2026 | clinicaltrials |
| NCT07713745 | Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)(PRIME-NF2) | not yet recruiting | Phase 2 | 200 | Beijing Tiantan HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07714070 | Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia(PKUPH-ORLPP-EC) | not yet recruiting | Phase 2 | 48 | Peking University People's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07714317 | Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet) | not yet recruiting | Phase 1 / Phase 2 | 90 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 20, 2026 | clinicaltrials |
| NCT07714551 | Zanzalintinib in Unresectable and Progressive MPGGs | not yet recruiting | Phase 2 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07715097 | Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma | not yet recruiting | Phase 2 | 30 | Beijing Tricision Biotherapeutics IncINDUSTRY | 0 | Jul 20, 2026 | clinicaltrials |
| NCT07715565 | Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial | not yet recruiting | Phase 2 | 66 | West China HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07715734 | Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma(CONTRAC-2) | not yet recruiting | Phase 2 | 22 | Washington University School of MedicineOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07227649 | NAC-REPAIR for Post-surgical Pain | not yet recruiting | Phase 2 | 80 | University of ArizonaOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07482605 | Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion | not yet recruiting | Phase 2 | 63 | Jiangmen Central HospitalOTHER | 0 | Jul 17, 2026 | clinicaltrials |
| NCT07709767 | Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 | 21 | Tang-Du HospitalOTHER | 0 | Jul 17, 2026 | clinicaltrials |
| NCT07711067 | A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer(MATTERS-2) | not yet recruiting | Phase 2 / Phase 3 | 95 | ElmediXINDUSTRY | 2 | Jul 17, 2026 | clinicaltrials |
| NCT07711483 | GLORY: Glofit-GemOx With Liso-Cel For Lymphoma(GLORY) | not yet recruiting | Phase 2 | 56 | Massachusetts General HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07712094 | AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer | not yet recruiting | Phase 2 | 56 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07064902 | Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07686926 | Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II | not yet recruiting | Phase 2 | 36 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 16, 2026 | clinicaltrials |
| NCT07706959 | New Genotype-guided Treatment in Newly Diagnosed PTCL(G08) | not yet recruiting | Phase 1 / Phase 2 | 108 | Ruijin HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07707882 | Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor(NEXPERT) | not yet recruiting | Phase 2 | 84 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07707947 | Selumetinib for NF2-Related Schwannomatosis(ASSIST) | not yet recruiting | Phase 2 | 20 | Beijing Tiantan HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07707973 | Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma(Nimotuzumab) | not yet recruiting | Phase 2 | 50 | Tianjin First Central HospitalOTHER | 0 | Jul 16, 2026 | clinicaltrials |
| NCT07708285 | Luvometinib in Combination With Serplulimab for NF2-Related Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Beijing Tiantan HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07709585 | Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients(BE-MASTER) | not yet recruiting | Phase 2 | 124 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07164469 | Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma | not yet recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07450183 | Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 | not yet recruiting | Phase 2 | 33 | Henry Ford Health SystemOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07521670 | Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)(STRAP) | not yet recruiting | Phase 2 | 68 | National Cancer Centre, SingaporeOTHER | 4 | Jul 15, 2026 | clinicaltrials |
| NCT07653438 | In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy(PulmoPrint) | not yet recruiting | Phase 2 | 20 | University Medical Center GroningenOTHER | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07662720 | A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer(MORALE-HN01) | not yet recruiting | Phase 1 / Phase 2 | 18 | Glycyx TherapeuticsINDUSTRY | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07704645 | The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 180 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705308 | A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma | not yet recruiting | Phase 2 | 140 | Ruijin HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705919 | DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 50 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07575724 | Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma | not yet recruiting | Phase 2 | 3,300 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07698080 | Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation | not yet recruiting | Phase 2 | 60 | Hematology department of the 920th hospitalOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07701122 | Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07701681 | Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 | 75 | Sun Yat-sen UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07701941 | A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 220 | Daiichi SankyoINDUSTRY | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07702851 | A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP | not yet recruiting | Phase 2 | 47 | Yonsei UniversityOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07599423 | A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 96 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07631325 | Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma(MORALE-MM) | not yet recruiting | Phase 1 / Phase 2 | 28 | John KirkwoodOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07638722 | Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment | not yet recruiting | Phase 2 | 138 | SWOG Cancer Research NetworkNETWORK | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07697443 | Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects | not yet recruiting | Phase 1 / Phase 2 | 306 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07698054 | Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer | not yet recruiting | Phase 2 | 130 | Henan Cancer HospitalOTHER_GOV | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07625930 | RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial(RESTAGE) | not yet recruiting | Phase 2 | 184 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07637851 | Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer(RegeNovar) | not yet recruiting | Phase 1 / Phase 2 | 43 | ARCAGY/ GINECO GROUPOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07678593 | A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation | not yet recruiting | Phase 1 / Phase 2 | 222 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 2 | Jul 10, 2026 | clinicaltrials |
| NCT07681297 | Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease(TIBEC) | not yet recruiting | Phase 1 / Phase 2 | 154 | National University Hospital, SingaporeOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07695740 | Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma | not yet recruiting | Phase 2 | 64 | Excyte Biopharma LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 21, 2026source: clinicaltrials